Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

'RNA fishing' technique identifies several proteins involved in the progression of melanoma

Researchers at the Centre for Genomic Regulation have identified several proteins involved in the progression of melanoma, the deadliest form of skin cancer.

3 Aug 2022

Alliance MCED Biobank Study may provide greater understanding of how to detect multiple cancers

The Alliance for Clinical Trials in Oncology, in partnership with the National Cancer Institute, part of the National Institutes of Health, today announced the opening of a new study for participant enrollment that aims to obtain a reference set of blood samples from newly diagnosed patients with cancer and healthy individuals without cancer to include in a future study to assess the utility of early cancer detection blood tests.

1 Aug 2022

How and when do de novo SARS-CoV-2 spike mutations emerge?

Researchers evaluated viral mutations in two patients with persistent SARS-CoV-2 infection.

1 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Tannins as therapeutic agents against SARS-CoV-2

Researchers reviewed tannins as therapeutic agents against SARS-CoV-2.

29 Jul 2022

Efficacy of COVID mRNA vaccines among patients on CAR‐T‐lymphocyte therapy

Researchers evaluate the effectiveness of mRNA COVID-19 vaccines among patients receiving CAR‐T‐lymphocyte therapy.

27 Jul 2022

New 'decoy receptor' molecules inhibit growth of multiple myeloma and diffuse large B cell lymphoma in mice

Researchers at Stanford University have developed "decoy receptor" molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice.

26 Jul 2022

Improving the immune defenses against blood cancer

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.

22 Jul 2022

International Agency for Research on Cancer classifies firefighting as carcinogenic

The International Agency for Research on Cancer recently classified occupational exposure as a firefighter as carcinogenic, changing the previous classification of possibly carcinogenic.

20 Jul 2022

Charged nanoparticles combined with a vaccine effective in eliminating melanoma tumors in mice

Cancers in humans have all sorts of ways to survive and thrive: Cells and tumors alike engage in devious means to deflect, deceive, and evade detection by our bodies’ immune systems.

20 Jul 2022

Pain control method has revolutionized the experience for bone marrow donors, reduced the need for opioids

Sharing gifts is a favorite way to sustain connection across peoples and cultures worldwide, but with bone marrow donation the gift-giving act is accompanied by uncomfortable side effects to the donor, making it a truly selfless expression of kindness.

19 Jul 2022

Addition of brentuximab vedotin to chemotherapy has a positive impact for patients with Hodgkin lymphoma

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone.

14 Jul 2022

Bioactive compounds in a marine sponge show potential to kill antibiotic-resistant bacteria

A research group led by scientists at the University of São Paulo (USP) in São Carlos, Brazil, has identified a number of bioactive compounds in a marine sponge collected on Fernando de Noronha, an archipelago about 400 km off the coast of Brazil's Northeast region.

13 Jul 2022

NCCN publishes new guidelines for treating pediatric CNS cancers

Today, the National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers.

12 Jul 2022

In America, cancer patients endure debt on top of disease

Jeni Rae Peters would make promises to herself as she lay awake nights after being diagnosed with breast cancer two years ago.

9 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Intrahost genetic diversity and evolution of the SARS-CoV-2 B.1.517 lineage during chronic infection of an immunocompromised individual

Researchers investigated the intrahost evolution and genetic diversity of the SARS-CoV-2 B.1.517 variant in an immunosuppressed person with chronic COVID-19.

6 Jul 2022

Remdesivir resistance in renal transplant patients with long COVID-19

A new study has reported two renal transplant cases, in which individuals, after being exposed to remdesivir, developed a resistance to the drug.

1 Jul 2022

Analysis finds variation in the management of mantle cell lymphoma across clinical settings

There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell Medicine and other leading health institutions.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.